{"gene":"FAAH","run_date":"2026-04-28T17:46:03","timeline":{"discoveries":[{"year":2009,"finding":"PF-3845 is a covalent FAAH inhibitor that carbamylates the active-site serine nucleophile of FAAH, as confirmed by mechanistic and structural studies. It selectively inhibits FAAH in vivo (verified by activity-based protein profiling), raises brain anandamide levels for up to 24 hours, and produces CB1 receptor-dependent reductions in inflammatory pain.","method":"Mechanistic studies (active-site carbamylation), structural studies, activity-based protein profiling, in vivo pharmacology with CB1 antagonist","journal":"Chemistry & biology","confidence":"High","confidence_rationale":"Tier 1 — covalent mechanism confirmed by structural and mechanistic studies with multiple orthogonal methods in a single study","pmids":["19389627"],"is_preprint":false},{"year":2008,"finding":"Crystal structure of humanized rat FAAH (h/rFAAH) complexed with inhibitor PF-750 at 2.75-Å resolution revealed the structural basis for species selectivity of FAAH inhibitors. The active sites of rat and human FAAH were interconverted by site-directed mutagenesis, producing a protein with human FAAH inhibitor-sensitivity but rat FAAH expression yield.","method":"X-ray crystallography, site-directed mutagenesis, inhibitor profiling","journal":"Proceedings of the National Academy of Sciences of the United States of America","confidence":"High","confidence_rationale":"Tier 1 — crystal structure with functional mutagenesis validation","pmids":["18753625"],"is_preprint":false},{"year":2011,"finding":"PF-04457845 inhibits FAAH by a covalent, irreversible mechanism involving carbamylation of the active-site serine nucleophile (kinact/Ki = 40,300 M⁻¹s⁻¹; IC50 = 7.2 nM for human FAAH), with exquisite selectivity over other serine hydrolases as demonstrated by competitive activity-based protein profiling.","method":"In vitro enzyme kinetics, active-site carbamylation mechanism, competitive activity-based protein profiling","journal":"ACS medicinal chemistry letters","confidence":"High","confidence_rationale":"Tier 1 — covalent catalytic mechanism confirmed by kinetics and ABPP selectivity profiling","pmids":["21666860"],"is_preprint":false},{"year":2000,"finding":"FAAH is a serine hydrolase containing an amidase domain with a serine catalytic nucleophile responsible for hydrolysis of anandamide and related fatty acid amides. Conserved domains include a hydrophobic domain important for self-association and a proline-rich domain potentially important for subcellular localization. Recombinant FAAH was purified and characterized following cloning from rat, mouse, human, and pig.","method":"cDNA cloning, recombinant protein purification, domain mutagenesis/sequence analysis, enzyme activity assays","journal":"Chemistry and physics of lipids","confidence":"High","confidence_rationale":"Tier 1 — foundational cloning and biochemical characterization replicated across multiple species","pmids":["11106785"],"is_preprint":false},{"year":2011,"finding":"A catalytically silent splice variant of FAAH-1 (termed FLAT, FAAH-like anandamide transporter) lacked amidase activity but bound anandamide with low micromolar affinity and facilitated its translocation into cells, identifying it as a molecular component of anandamide transport in neural cells. Known anandamide transport inhibitors (AM404, OMDM-1) blocked these effects.","method":"Molecular cloning, binding assays, cellular uptake assays, pharmacological inhibition, in vivo antinociceptive studies","journal":"Nature neuroscience","confidence":"Medium","confidence_rationale":"Tier 2 — multiple in vitro and in vivo methods but disputed by follow-up study (PMID:24223930)","pmids":["22101642"],"is_preprint":false},{"year":2013,"finding":"A follow-up study found that FLAT displayed residual catalytic activity sensitive to FAAH inhibitors and abolished by mutation of its catalytic serine; overexpression of FLAT potentiated AEA cellular uptake in a manner dependent on its catalytic activity rather than transport function. FLAT was not detected in multiple tissues examined, suggesting it does not serve as a global intracellular AEA carrier.","method":"PCR-based generation of FLAT construct, mutagenesis of catalytic serine, cellular uptake assays in FAAH-expressing and FAAH-deficient cells, immunofluorescence localization","journal":"PloS one","confidence":"Medium","confidence_rationale":"Tier 2 — mutagenesis and multiple cell-based assays, but contradicts the original FLAT characterization","pmids":["24223930"],"is_preprint":false},{"year":2014,"finding":"Membrane lipid composition modulates FAAH structure, subcellular localization, and activity. The FAAH dimer is stabilized by the lipid bilayer, shows higher membrane-binding affinity and enzymatic activity in membranes containing both cholesterol and the substrate anandamide (AEA). Co-localization of cholesterol, AEA, and FAAH in mouse neuroblastoma cells suggests cholesterol increases FAAH substrate accessibility.","method":"Combined experimental (enzyme activity assays, co-localization imaging) and computational (molecular dynamics simulation) approach","journal":"The Biochemical journal","confidence":"Medium","confidence_rationale":"Tier 2 — multiple orthogonal methods (biochemical + computational + cell imaging) from a single study","pmids":["24215562"],"is_preprint":false},{"year":2020,"finding":"FAAH is an allosteric homodimeric enzyme: occupation of only one of the two active sites is sufficient to fully block catalysis. A single W445Y substitution eliminated allostery (Hill coefficient ~1.0) without reducing activity, while F432A reduced specific activity but retained allostery. Human FAAH also showed allosteric AEA hydrolysis (Hill coefficient ~1.9), implicating W445 at the dimer interface as a key allosteric residue.","method":"Site-directed mutagenesis, enzyme kinetics (Hill coefficient analysis), stoichiometric inhibitor titration of human and rat FAAH","journal":"Scientific reports","confidence":"High","confidence_rationale":"Tier 1 — reconstituted kinetic analysis with mutagenesis of specific residues in both human and rat FAAH","pmids":["32041998"],"is_preprint":false},{"year":2003,"finding":"Progesterone activates the FAAH promoter in human T lymphocytes through the transcription factor Ikaros. Mutation of Ikaros binding sites (ERE2/3) in the FAAH promoter prevented progesterone-induced FAAH transcription. Leptin additively activates FAAH expression via a cAMP response element-like site. Progesterone-induced FAAH upregulation decreased cellular anandamide levels.","method":"Transient expression/reporter assays, EMSA and supershift assays, site-directed mutagenesis of promoter, enzyme activity assays","journal":"The Journal of biological chemistry","confidence":"High","confidence_rationale":"Tier 1/2 — promoter mutagenesis, EMSA, and functional reporter assays with multiple orthogonal methods","pmids":["12799380"],"is_preprint":false},{"year":2012,"finding":"Estrogen (E2) directly induces FAAH transcription in mouse Sertoli cells via estrogen receptor β binding to two proximal ERE sequences (ERE2/3) in the faah promoter. The histone demethylase LSD1 is associated with these sites and mediates E2 induction of FAAH expression. E2 induced epigenetic modifications (decreased DNA methylation at CpG and H3K9 methylation) compatible with transcriptional activation. FAAH silencing abolished E2-mediated protection against anandamide-induced apoptosis.","method":"Luciferase reporter assays, promoter mutagenesis, ChIP, bisulfite methylation analysis, FAAH siRNA knockdown, apoptosis assays","journal":"Cellular and molecular life sciences : CMLS","confidence":"High","confidence_rationale":"Tier 1/2 — multiple orthogonal methods including ChIP, mutagenesis, and functional rescue experiments","pmids":["22802127"],"is_preprint":false},{"year":2017,"finding":"Activity-based proteomic profiling of the FAAH inhibitor BIA 10-2474 in human cells and tissues revealed that it inhibits several lipases beyond FAAH that are not targeted by the selective inhibitor PF04457845. BIA 10-2474, but not PF04457845, produced substantial alterations in lipid networks in human cortical neurons, indicating that promiscuous lipase inhibition causes metabolic dysregulation in the nervous system.","method":"Activity-based protein profiling (ABPP) in human cells/tissues, lipid network analysis in human cortical neurons","journal":"Science (New York, N.Y.)","confidence":"High","confidence_rationale":"Tier 1/2 — systematic proteome-wide ABPP combined with lipidomics in human tissue; high citation count","pmids":["28596366"],"is_preprint":false},{"year":2015,"finding":"The common human FAAH C385A polymorphism (rs324420) reduces FAAH expression and activity, thereby increasing anandamide levels. Knock-in mice recapitulating this variant showed selectively enhanced fronto-amygdala connectivity, facilitated fear extinction learning, and decreased anxiety-like behaviors, paralleling effects in human A-allele carriers.","method":"Knock-in mouse generation, FAAH activity and expression assays, behavioral testing, neuroimaging (fMRI connectivity), parallel human genetics analysis","journal":"Nature communications","confidence":"High","confidence_rationale":"Tier 2 — translational knock-in model with biochemical, behavioral, and neuroimaging validation replicated in humans","pmids":["25731744"],"is_preprint":false},{"year":2018,"finding":"FAAH activity is required for leptin's hypophagic effects. Leptin-deficient mice showed elevated hypothalamic anandamide and reduced FAAH activity; leptin administration to WT mice reduced AEA and increased FAAH activity. FAAH C385A knock-in mice with reduced FAAH activity were unresponsive to leptin-induced reductions in food intake and body weight. Pharmacological FAAH inhibition was sufficient to prevent leptin-mediated changes in body weight and food intake.","method":"Leptin administration to WT/ob/ob mice (endocannabinoid measurement by mass spectrometry), FAAH C385A knock-in mice, FAAH inhibitor pharmacology, high-fat diet challenge","journal":"Proceedings of the National Academy of Sciences of the United States of America","confidence":"High","confidence_rationale":"Tier 2 — multiple genetic and pharmacological approaches with biochemical endpoint measurements","pmids":["29967158"],"is_preprint":false},{"year":2012,"finding":"FAAH anti-allodynic effects in LPS-induced tactile allodynia are mediated specifically by neuronal FAAH: mice expressing FAAH exclusively in the nervous system (under neural specific enolase promoter) did not show the anti-allodynic phenotype of wild-type mice treated with FAAH inhibitors. The anti-allodynic effects required activation of both CB1 and CB2 receptors.","method":"Neuron-specific FAAH rescue mouse model, pharmacological inhibition (URB597, OL-135, PF-3845), endocannabinoid mass spectrometry, CB1/CB2 antagonist pharmacology","journal":"British journal of pharmacology","confidence":"High","confidence_rationale":"Tier 2 — genetic rescue model combined with pharmacological receptor characterization and biochemical measurements","pmids":["21506952"],"is_preprint":false},{"year":2014,"finding":"In the periaqueductal grey (PAG), anandamide (but not 2-AG) produced reduction of inhibitory GABAergic transmission via disinhibition. This AEA-induced suppression was enhanced by the FAAH inhibitor URB597, while 2-AG-induced suppression was unmasked only by the MAGL inhibitor JZL184. Combined FAAH/MAGL inhibition enhanced tonic disinhibition, consistent with analgesic action.","method":"In vitro electrophysiological recordings from rat midbrain PAG slices, cannabinoid receptor antagonist pharmacology","journal":"British journal of pharmacology","confidence":"High","confidence_rationale":"Tier 1/2 — in vitro electrophysiology with defined circuit-level mechanism and receptor pharmacology","pmids":["25041240"],"is_preprint":false},{"year":2008,"finding":"FAAH was unexpectedly localized to the nucleus of invasive extravillous trophoblasts in recurrent miscarriage cases (verified by western blotting of subcellular fractions and confocal microscopy), as opposed to cytoplasmic localization in normal pregnancies. FAAH was overexpressed in trophoblasts that had invaded the decidua in 67% of recurrent miscarriage cases but not in normal pregnancies.","method":"Immunohistochemistry, subcellular fractionation with western blotting, confocal microscopy","journal":"Placenta","confidence":"Medium","confidence_rationale":"Tier 2/3 — subcellular localization confirmed by fractionation and confocal; functional significance not fully established","pmids":["18805581"],"is_preprint":false},{"year":2021,"finding":"FAAH genetic inactivation in the 5xFAD Alzheimer's disease mouse model rescued hippocampal synaptic plasticity (basal synaptic transmission and LTP at CA3-CA1 synapses) and restored dendritic spine density in CA1 pyramidal neurons. The LTP rescue was independent of CB1R and TRPV1 receptors. FAAH deletion upregulated microglial phagocytic factors (TREM2, CTSD) and amyloid beta clearance factors (complement C3, C3AR), potentiating amyloid beta phagocytosis.","method":"Electrophysiology (LTP recording), flow cytometry, dendritic spine morphometry, molecular analysis of microglial markers in 5xFAD/FAAH⁻/⁻ mice","journal":"Journal of neuroinflammation","confidence":"Medium","confidence_rationale":"Tier 2 — multiple orthogonal methods (electrophysiology, morphometry, molecular) in a defined genetic model","pmids":["34587978"],"is_preprint":false},{"year":2012,"finding":"Hyperglycemia downregulates FAAH-1 expression in retinal pigment epithelial cells, leading to elevated anandamide and upregulated CB1 receptor expression. Overexpression of FAAH-1 blocked high-glucose-induced CB1R internalization, ROS generation, and apoptosis (reduced Bax/Bcl-2 ratio and caspase activation), establishing FAAH-1 as a regulator of CB1R-mediated apoptosis in diabetic retinopathy.","method":"Overexpression of FAAH-1, siRNA knockdown of CB1R, CB1R antagonist (AM251), ROS measurement, apoptosis assays (caspase-3/9, PARP cleavage, cell viability)","journal":"Journal of cellular physiology","confidence":"Medium","confidence_rationale":"Tier 2 — multiple loss/gain-of-function experiments with mechanistic biochemical readouts","pmids":["21442624"],"is_preprint":false}],"current_model":"FAAH is an integral membrane serine hydrolase that forms a homodimer and operates via an allosteric catalytic mechanism in which occupancy of one active-site serine nucleophile is sufficient to block both subunits; it degrades anandamide and related fatty acid amide signaling lipids by carbamylation/hydrolysis, with its activity modulated by membrane lipid composition (cholesterol), regulated transcriptionally by progesterone (via Ikaros), estrogen (via ERβ/LSD1), and leptin (via CRE-like elements), and positioned as the primary catabolic determinant of endocannabinoid tone in pain, anxiety, fear extinction, and metabolic signaling circuits."},"narrative":{"teleology":[{"year":2000,"claim":"Identification of FAAH as a serine hydrolase with an amidase catalytic domain responsible for anandamide degradation established the molecular identity and enzymatic mechanism of the primary endocannabinoid-degrading enzyme.","evidence":"cDNA cloning from rat, mouse, human, and pig with recombinant protein purification and domain analysis","pmids":["11106785"],"confidence":"High","gaps":["No high-resolution structure yet available","Membrane topology and oligomeric state not resolved","Physiological substrate hierarchy not defined"]},{"year":2003,"claim":"Discovery that progesterone activates FAAH transcription through Ikaros binding to ERE2/3 sites, and leptin acts additively via a CRE-like element, revealed how hormonal signals control endocannabinoid tone by regulating FAAH expression.","evidence":"Promoter-reporter assays, EMSA/supershift, site-directed mutagenesis in human T lymphocytes","pmids":["12799380"],"confidence":"High","gaps":["Physiological relevance of Ikaros-mediated regulation in non-immune cells not tested","Leptin-FAAH transcriptional pathway intermediates not fully mapped"]},{"year":2008,"claim":"The crystal structure of humanized rat FAAH with an inhibitor revealed the structural basis for species-selective inhibitor binding and enabled rational drug design by interconverting rat and human active sites through mutagenesis.","evidence":"X-ray crystallography at 2.75 Å resolution with site-directed mutagenesis","pmids":["18753625"],"confidence":"High","gaps":["Full-length human FAAH structure not yet solved","Membrane-embedded dimer structure unknown"]},{"year":2009,"claim":"Demonstration that PF-3845 covalently carbamylates the FAAH active-site serine, selectively raises brain anandamide for 24 hours, and produces CB1-dependent analgesia established the in vivo proof-of-concept that selective FAAH inhibition modulates endocannabinoid signaling to reduce pain.","evidence":"Structural/mechanistic studies, activity-based protein profiling, in vivo pharmacology with CB1 antagonist","pmids":["19389627"],"confidence":"High","gaps":["Contribution of non-anandamide FAAH substrates to analgesic effect unclear","Long-term consequences of sustained FAAH inhibition not assessed"]},{"year":2012,"claim":"Estrogen was shown to induce FAAH transcription via ERβ binding to proximal ERE sites with recruitment of the histone demethylase LSD1, causing epigenetic remodeling that protects Sertoli cells from anandamide-induced apoptosis, broadening the hormonal control of FAAH to include estrogen-dependent epigenetic mechanisms.","evidence":"ChIP, luciferase reporters, promoter mutagenesis, bisulfite methylation, FAAH siRNA knockdown, apoptosis assays in mouse Sertoli cells","pmids":["22802127"],"confidence":"High","gaps":["Whether ERβ/LSD1-mediated regulation operates in neural tissues not tested","Interplay between progesterone/Ikaros and estrogen/ERβ pathways not examined"]},{"year":2012,"claim":"Tissue-specific FAAH rescue experiments showed that non-neuronal FAAH is required for anti-allodynic effects of FAAH inhibitors in inflammatory pain, acting through both CB1 and CB2 receptors, clarifying that peripheral endocannabinoid metabolism is a key analgesic site.","evidence":"Neuron-specific FAAH rescue mouse model, pharmacological inhibition, CB1/CB2 antagonists, endocannabinoid mass spectrometry","pmids":["21506952"],"confidence":"High","gaps":["Specific peripheral cell type(s) responsible not identified","Relative contribution of peripheral vs. central FAAH in chronic pain models unknown"]},{"year":2014,"claim":"Cholesterol was found to enhance FAAH membrane binding affinity, dimer stability, and enzymatic activity, with co-localization of cholesterol, anandamide, and FAAH in neuroblastoma cells, establishing membrane lipid composition as a regulator of FAAH catalysis.","evidence":"Combined enzyme activity assays, co-localization imaging, and molecular dynamics simulation in mouse neuroblastoma cells","pmids":["24215562"],"confidence":"Medium","gaps":["In vivo validation of cholesterol-dependent activity modulation not performed","Whether cholesterol acts by altering substrate presentation vs. direct protein interaction not resolved"]},{"year":2015,"claim":"The human FAAH C385A polymorphism was shown via knock-in mice to reduce FAAH expression and activity, elevate anandamide, enhance fronto-amygdala connectivity, and facilitate fear extinction, directly linking FAAH genetic variation to anxiety and emotional learning circuits.","evidence":"Knock-in mouse generation, FAAH activity assays, behavioral testing, fMRI connectivity, parallel human genotype-phenotype analysis","pmids":["25731744"],"confidence":"High","gaps":["Downstream signaling mediators of enhanced fear extinction not identified","Whether effects are fully CB1-dependent not tested"]},{"year":2017,"claim":"Proteome-wide activity profiling revealed that the clinical FAAH inhibitor BIA 10-2474 inhibited multiple off-target lipases, causing lipid network dysregulation in human cortical neurons, while the selective inhibitor PF04457845 did not—clarifying that toxicity in the BIA 10-2474 trial arose from off-target effects rather than FAAH inhibition per se.","evidence":"Activity-based protein profiling in human cells and tissues, lipidomics in human cortical neurons","pmids":["28596366"],"confidence":"High","gaps":["Complete target list of BIA 10-2474 metabolites not characterized","Whether any FAAH-dependent lipid changes contribute to neurotoxicity not excluded"]},{"year":2018,"claim":"FAAH was established as a required effector of leptin's hypophagic action: leptin increases hypothalamic FAAH activity to reduce anandamide, and C385A knock-in mice or pharmacological FAAH inhibition abolished leptin-induced reductions in food intake and body weight.","evidence":"Leptin administration in WT/ob/ob mice, endocannabinoid mass spectrometry, FAAH C385A knock-in mice, FAAH inhibitor pharmacology","pmids":["29967158"],"confidence":"High","gaps":["Transcriptional vs. post-translational mechanism of leptin-induced FAAH activation not distinguished in vivo","Whether other FAAH substrates beyond AEA contribute to metabolic effects unknown"]},{"year":2020,"claim":"Kinetic analysis revealed FAAH operates as an allosteric homodimer where occupation of one active site blocks both subunits, with W445 at the dimer interface mediating inter-subunit communication, fundamentally redefining the stoichiometry of FAAH inhibition.","evidence":"Hill coefficient analysis, stoichiometric inhibitor titration, site-directed mutagenesis (W445Y, F432A) of human and rat FAAH","pmids":["32041998"],"confidence":"High","gaps":["Structural basis for allosteric communication not determined at atomic level","Whether allostery is substrate-dependent not tested","In vivo relevance of half-site inhibition not demonstrated"]},{"year":2021,"claim":"FAAH genetic deletion rescued hippocampal synaptic plasticity and dendritic spine density in an Alzheimer's model via a CB1R/TRPV1-independent mechanism involving upregulation of microglial phagocytic and amyloid-clearance pathways, extending FAAH function to neuroinflammation and neurodegeneration.","evidence":"Electrophysiology, dendritic spine morphometry, flow cytometry, and molecular analysis in 5xFAD/FAAH−/− mice","pmids":["34587978"],"confidence":"Medium","gaps":["Identity of the FAAH-derived lipid mediator(s) responsible for microglial activation unknown","CB1R/TRPV1-independent mechanism not molecularly defined","Replication in independent AD models needed"]},{"year":null,"claim":"The structural basis for FAAH allosteric communication across the dimer interface, the identity of FAAH substrates beyond anandamide that drive its metabolic and neuroinflammatory functions, and the mechanism by which FAAH loss activates microglial phagocytic programs remain unresolved.","evidence":"","pmids":[],"confidence":"High","gaps":["Full-length membrane-embedded human FAAH dimer structure not solved","Substrate hierarchy in vivo not systematically defined","Mechanism of FAAH-dependent microglial reprogramming unknown"]}],"mechanism_profile":{"molecular_activity":[{"term_id":"GO:0016787","term_label":"hydrolase activity","supporting_discovery_ids":[0,2,3,7]},{"term_id":"GO:0140096","term_label":"catalytic activity, acting on a protein","supporting_discovery_ids":[3,0,2]}],"localization":[{"term_id":"GO:0005886","term_label":"plasma membrane","supporting_discovery_ids":[3,6]},{"term_id":"GO:0005634","term_label":"nucleus","supporting_discovery_ids":[15]}],"pathway":[{"term_id":"R-HSA-162582","term_label":"Signal Transduction","supporting_discovery_ids":[11,12,14]},{"term_id":"R-HSA-112316","term_label":"Neuronal System","supporting_discovery_ids":[11,14,16]}],"complexes":["FAAH homodimer"],"partners":["IKZF1","ESR2","KDM1A","CNR1","CNR2"],"other_free_text":[]},"mechanistic_narrative":"FAAH is an integral membrane serine hydrolase that degrades anandamide and related fatty acid amides, serving as the primary catabolic enzyme controlling endocannabinoid tone in the nervous system and peripheral tissues [PMID:11106785, PMID:19389627]. It functions as an allosteric homodimer in which occupation of a single active-site serine nucleophile is sufficient to block catalysis across both subunits, with tryptophan 445 at the dimer interface mediating inter-subunit communication [PMID:32041998]. FAAH activity is modulated by membrane cholesterol content, which enhances substrate accessibility and enzymatic activity [PMID:24215562], and its transcription is induced by progesterone (via Ikaros), estrogen (via ERβ/LSD1-mediated epigenetic remodeling), and leptin (via a CRE-like element) [PMID:12799380, PMID:22802127, PMID:29967158]. The common human C385A polymorphism reduces FAAH expression and elevates anandamide levels, enhancing fronto-amygdala connectivity, facilitating fear extinction, decreasing anxiety, and attenuating leptin-mediated hypophagia, establishing FAAH as a critical determinant of endocannabinoid signaling in pain, anxiety, metabolic regulation, and neuroinflammation [PMID:25731744, PMID:29967158, PMID:21506952, PMID:34587978]."},"prefetch_data":{"uniprot":{"accession":"O00519","full_name":"Fatty-acid amide hydrolase 1","aliases":["Anandamide amidohydrolase 1","Fatty acid ester hydrolase","Oleamide hydrolase 1"],"length_aa":579,"mass_kda":63.1,"function":"Catalyzes the hydrolysis of endogenous amidated lipids like the sleep-inducing lipid oleamide ((9Z)-octadecenamide), the endocannabinoid anandamide (N-(5Z,8Z,11Z,14Z-eicosatetraenoyl)-ethanolamine), as well as other fatty amides, to their corresponding fatty acids, thereby regulating the signaling functions of these molecules (PubMed:17015445, PubMed:19926788, PubMed:9122178). Hydrolyzes polyunsaturated substrate anandamide preferentially as compared to monounsaturated substrates (PubMed:17015445, PubMed:9122178). It can also catalyze the hydrolysis of the endocannabinoid 2-arachidonoylglycerol (2-(5Z,8Z,11Z,14Z-eicosatetraenoyl)-glycerol) (PubMed:21049984). FAAH cooperates with PM20D1 in the hydrolysis of amino acid-conjugated fatty acids such as N-fatty acyl glycine and N-fatty acyl-L-serine, thereby acting as a physiological regulator of specific subsets of intracellular, but not of extracellular, N-fatty acyl amino acids (By similarity)","subcellular_location":"Endomembrane system; Cytoplasm, cytoskeleton","url":"https://www.uniprot.org/uniprotkb/O00519/entry"},"depmap":{"release":"DepMap","has_data":true,"is_common_essential":false,"resolved_as":"","url":"https://depmap.org/portal/gene/FAAH","classification":"Not Classified","n_dependent_lines":20,"n_total_lines":1208,"dependency_fraction":0.016556291390728478},"opencell":{"profiled":false,"resolved_as":"","ensg_id":"","cell_line_id":"","localizations":[],"interactors":[],"url":"https://opencell.sf.czbiohub.org/search/FAAH","total_profiled":1310},"omim":[{"mim_id":"618377","title":"PAIN SENSITIVITY QUANTITATIVE TRAIT LOCUS 1; PAINQTL1","url":"https://www.omim.org/entry/618377"},{"mim_id":"618375","title":"FATTY ACID AMIDE HYDROLASE PSEUDOGENE 1; FAAHP1","url":"https://www.omim.org/entry/618375"},{"mim_id":"611026","title":"FATTY ACID 2-HYDROXYLASE; FA2H","url":"https://www.omim.org/entry/611026"},{"mim_id":"606581","title":"POLYSUBSTANCE ABUSE, SUSCEPTIBILITY TO; PSAB","url":"https://www.omim.org/entry/606581"},{"mim_id":"605168","title":"FATTY ACID-BINDING PROTEIN 5; FABP5","url":"https://www.omim.org/entry/605168"}],"hpa":{"profiled":true,"resolved_as":"","reliability":"Approved","locations":[{"location":"Cytosol","reliability":"Approved"}],"tissue_specificity":"Low tissue specificity","tissue_distribution":"Detected in all","driving_tissues":[],"url":"https://www.proteinatlas.org/search/FAAH"},"hgnc":{"alias_symbol":["FAAH-1","FAAH1"],"prev_symbol":[]},"alphafold":{"accession":"Q7L5A8","domains":[{"cath_id":"3.10.120.10","chopping":"10-86","consensus_level":"high","plddt":87.9726,"start":10,"end":86},{"cath_id":"-","chopping":"160-360","consensus_level":"high","plddt":94.5629,"start":160,"end":360}],"viewer_url":"https://alphafold.ebi.ac.uk/entry/Q7L5A8","model_url":"https://alphafold.ebi.ac.uk/files/AF-Q7L5A8-F1-model_v6.cif","pae_url":"https://alphafold.ebi.ac.uk/files/AF-Q7L5A8-F1-predicted_aligned_error_v6.png","plddt_mean":85.12},"mouse_models":{"mgi_url":"https://www.informatics.jax.org/marker/summary?nomen=FAAH","jax_strain_url":"https://www.jax.org/strain/search?query=FAAH"},"sequence":{"accession":"Q7L5A8","fasta_url":"https://rest.uniprot.org/uniprotkb/Q7L5A8.fasta","uniprot_url":"https://www.uniprot.org/uniprotkb/Q7L5A8/entry","alphafold_viewer_url":"https://alphafold.ebi.ac.uk/entry/Q7L5A8"}},"corpus_meta":[{"pmid":"19389627","id":"PMC_19389627","title":"Discovery and characterization of a highly selective FAAH inhibitor that reduces inflammatory pain.","date":"2009","source":"Chemistry & biology","url":"https://pubmed.ncbi.nlm.nih.gov/19389627","citation_count":373,"is_preprint":false},{"pmid":"16834756","id":"PMC_16834756","title":"Pharmacological profile of the selective FAAH inhibitor KDS-4103 (URB597).","date":"2006","source":"CNS drug reviews","url":"https://pubmed.ncbi.nlm.nih.gov/16834756","citation_count":345,"is_preprint":false},{"pmid":"19918051","id":"PMC_19918051","title":"Dual blockade of FAAH and MAGL identifies behavioral processes regulated by endocannabinoid crosstalk in vivo.","date":"2009","source":"Proceedings of the National Academy of Sciences of the United States of America","url":"https://pubmed.ncbi.nlm.nih.gov/19918051","citation_count":310,"is_preprint":false},{"pmid":"28596366","id":"PMC_28596366","title":"Activity-based protein profiling reveals off-target proteins of the FAAH inhibitor BIA 10-2474.","date":"2017","source":"Science (New York, N.Y.)","url":"https://pubmed.ncbi.nlm.nih.gov/28596366","citation_count":242,"is_preprint":false},{"pmid":"16331291","id":"PMC_16331291","title":"Actions of the FAAH inhibitor URB597 in neuropathic and inflammatory chronic pain models.","date":"2006","source":"British journal of pharmacology","url":"https://pubmed.ncbi.nlm.nih.gov/16331291","citation_count":236,"is_preprint":false},{"pmid":"17709120","id":"PMC_17709120","title":"Reduced anxiety-like behaviour induced by genetic and pharmacological inhibition of the endocannabinoid-degrading enzyme fatty acid amide hydrolase (FAAH) is mediated by CB1 receptors.","date":"2007","source":"Neuropharmacology","url":"https://pubmed.ncbi.nlm.nih.gov/17709120","citation_count":227,"is_preprint":false},{"pmid":"25731744","id":"PMC_25731744","title":"FAAH genetic variation enhances fronto-amygdala function in mouse and human.","date":"2015","source":"Nature communications","url":"https://pubmed.ncbi.nlm.nih.gov/25731744","citation_count":225,"is_preprint":false},{"pmid":"12052036","id":"PMC_12052036","title":"The fatty acid amide hydrolase (FAAH).","date":"2002","source":"Prostaglandins, leukotrienes, and essential fatty acids","url":"https://pubmed.ncbi.nlm.nih.gov/12052036","citation_count":173,"is_preprint":false},{"pmid":"24325918","id":"PMC_24325918","title":"Amygdala FAAH and anandamide: mediating protection and recovery from stress.","date":"2013","source":"Trends in pharmacological sciences","url":"https://pubmed.ncbi.nlm.nih.gov/24325918","citation_count":172,"is_preprint":false},{"pmid":"16805835","id":"PMC_16805835","title":"Anandamide administration alone and after inhibition of fatty acid amide hydrolase (FAAH) increases dopamine levels in the nucleus accumbens shell in rats.","date":"2006","source":"Journal of neurochemistry","url":"https://pubmed.ncbi.nlm.nih.gov/16805835","citation_count":170,"is_preprint":false},{"pmid":"11106785","id":"PMC_11106785","title":"The fatty acid amide hydrolase (FAAH).","date":"2000","source":"Chemistry and physics of lipids","url":"https://pubmed.ncbi.nlm.nih.gov/11106785","citation_count":168,"is_preprint":false},{"pmid":"21666860","id":"PMC_21666860","title":"Discovery of PF-04457845: A Highly Potent, Orally Bioavailable, and Selective Urea FAAH Inhibitor.","date":"2011","source":"ACS medicinal chemistry letters","url":"https://pubmed.ncbi.nlm.nih.gov/21666860","citation_count":145,"is_preprint":false},{"pmid":"19184452","id":"PMC_19184452","title":"Targeting fatty acid amide hydrolase (FAAH) to treat pain and inflammation.","date":"2009","source":"The AAPS journal","url":"https://pubmed.ncbi.nlm.nih.gov/19184452","citation_count":135,"is_preprint":false},{"pmid":"18753625","id":"PMC_18753625","title":"Structure-guided inhibitor design for human FAAH by interspecies active site conversion.","date":"2008","source":"Proceedings of the National Academy of Sciences of the United States of America","url":"https://pubmed.ncbi.nlm.nih.gov/18753625","citation_count":133,"is_preprint":false},{"pmid":"22101642","id":"PMC_22101642","title":"A catalytically silent FAAH-1 variant drives anandamide transport in neurons.","date":"2011","source":"Nature neuroscience","url":"https://pubmed.ncbi.nlm.nih.gov/22101642","citation_count":129,"is_preprint":false},{"pmid":"18028339","id":"PMC_18028339","title":"5-Lipoxygenase and anandamide hydrolase (FAAH) mediate the antitumor activity of cannabidiol, a non-psychoactive cannabinoid.","date":"2007","source":"Journal of neurochemistry","url":"https://pubmed.ncbi.nlm.nih.gov/18028339","citation_count":114,"is_preprint":false},{"pmid":"19403796","id":"PMC_19403796","title":"Fatty acid amide hydrolase (FAAH) inhibition enhances memory acquisition through activation of PPAR-alpha nuclear receptors.","date":"2009","source":"Learning & memory (Cold Spring Harbor, N.Y.)","url":"https://pubmed.ncbi.nlm.nih.gov/19403796","citation_count":113,"is_preprint":false},{"pmid":"20010552","id":"PMC_20010552","title":"Individual and additive effects of the CNR1 and FAAH genes on brain response to marijuana cues.","date":"2009","source":"Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology","url":"https://pubmed.ncbi.nlm.nih.gov/20010552","citation_count":98,"is_preprint":false},{"pmid":"16448676","id":"PMC_16448676","title":"Increased ethanol consumption and preference and decreased ethanol sensitivity in female FAAH knockout mice.","date":"2006","source":"Neuropharmacology","url":"https://pubmed.ncbi.nlm.nih.gov/16448676","citation_count":94,"is_preprint":false},{"pmid":"21506952","id":"PMC_21506952","title":"The fatty acid amide hydrolase (FAAH) inhibitor PF-3845 acts in the nervous system to reverse LPS-induced tactile allodynia in mice.","date":"2012","source":"British journal of pharmacology","url":"https://pubmed.ncbi.nlm.nih.gov/21506952","citation_count":92,"is_preprint":false},{"pmid":"32867595","id":"PMC_32867595","title":"Targeting Endocannabinoid Signaling: FAAH and MAG Lipase Inhibitors.","date":"2020","source":"Annual review of pharmacology and toxicology","url":"https://pubmed.ncbi.nlm.nih.gov/32867595","citation_count":89,"is_preprint":false},{"pmid":"12799380","id":"PMC_12799380","title":"Progesterone activates fatty acid amide hydrolase (FAAH) promoter in human T lymphocytes through the transcription factor Ikaros. Evidence for a synergistic effect of leptin.","date":"2003","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/12799380","citation_count":89,"is_preprint":false},{"pmid":"23333350","id":"PMC_23333350","title":"Inhibition of FAAH and activation of PPAR: new approaches to the treatment of cognitive dysfunction and drug addiction.","date":"2013","source":"Pharmacology & therapeutics","url":"https://pubmed.ncbi.nlm.nih.gov/23333350","citation_count":87,"is_preprint":false},{"pmid":"19419760","id":"PMC_19419760","title":"Endocannabinoid system in first trimester placenta: low FAAH and high CB1 expression characterize spontaneous miscarriage.","date":"2009","source":"Placenta","url":"https://pubmed.ncbi.nlm.nih.gov/19419760","citation_count":86,"is_preprint":false},{"pmid":"14580383","id":"PMC_14580383","title":"Identification of the CB1 cannabinoid receptor and fatty acid amide hydrolase (FAAH) in the human placenta.","date":"2003","source":"Placenta","url":"https://pubmed.ncbi.nlm.nih.gov/14580383","citation_count":77,"is_preprint":false},{"pmid":"20029375","id":"PMC_20029375","title":"FAAH deficiency promotes energy storage and enhances the motivation for food.","date":"2009","source":"International journal of obesity (2005)","url":"https://pubmed.ncbi.nlm.nih.gov/20029375","citation_count":74,"is_preprint":false},{"pmid":"31945644","id":"PMC_31945644","title":"A perspective review on fatty acid amide hydrolase (FAAH) inhibitors as potential therapeutic agents.","date":"2019","source":"European journal of medicinal chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/31945644","citation_count":68,"is_preprint":false},{"pmid":"24811863","id":"PMC_24811863","title":"FAAH inhibition enhances anandamide mediated anti-tumorigenic effects in non-small cell lung cancer by downregulating the EGF/EGFR pathway.","date":"2014","source":"Oncotarget","url":"https://pubmed.ncbi.nlm.nih.gov/24811863","citation_count":61,"is_preprint":false},{"pmid":"32203086","id":"PMC_32203086","title":"Potential application of endocannabinoid system agents in neuropsychiatric and neurodegenerative diseases-focusing on FAAH/MAGL inhibitors.","date":"2020","source":"Acta pharmacologica Sinica","url":"https://pubmed.ncbi.nlm.nih.gov/32203086","citation_count":60,"is_preprint":false},{"pmid":"27005594","id":"PMC_27005594","title":"Genetically reduced FAAH activity may be a risk for the development of anxiety and depression in persons with repetitive childhood trauma.","date":"2016","source":"European neuropsychopharmacology : the journal of the European College of Neuropsychopharmacology","url":"https://pubmed.ncbi.nlm.nih.gov/27005594","citation_count":59,"is_preprint":false},{"pmid":"22140525","id":"PMC_22140525","title":"Endocannabinoid regulation of acute and protracted nicotine withdrawal: effect of FAAH inhibition.","date":"2011","source":"PloS one","url":"https://pubmed.ncbi.nlm.nih.gov/22140525","citation_count":58,"is_preprint":false},{"pmid":"22802127","id":"PMC_22802127","title":"The faah gene is the first direct target of estrogen in the testis: role of histone demethylase LSD1.","date":"2012","source":"Cellular and molecular life sciences : CMLS","url":"https://pubmed.ncbi.nlm.nih.gov/22802127","citation_count":55,"is_preprint":false},{"pmid":"17216208","id":"PMC_17216208","title":"The functional Pro129Thr variant of the FAAH gene is not associated with various fat accumulation phenotypes in a population-based cohort of 5,801 whites.","date":"2007","source":"Journal of molecular medicine (Berlin, Germany)","url":"https://pubmed.ncbi.nlm.nih.gov/17216208","citation_count":54,"is_preprint":false},{"pmid":"23891163","id":"PMC_23891163","title":"Macamides and their synthetic analogs: evaluation of in vitro FAAH inhibition.","date":"2013","source":"Bioorganic & medicinal chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/23891163","citation_count":53,"is_preprint":false},{"pmid":"29197803","id":"PMC_29197803","title":"Redox system and phospholipid metabolism in the kidney of hypertensive rats after FAAH inhibitor URB597 administration.","date":"2017","source":"Redox biology","url":"https://pubmed.ncbi.nlm.nih.gov/29197803","citation_count":53,"is_preprint":false},{"pmid":"19002671","id":"PMC_19002671","title":"Intermediate cannabis dependence phenotypes and the FAAH C385A variant: an exploratory analysis.","date":"2008","source":"Psychopharmacology","url":"https://pubmed.ncbi.nlm.nih.gov/19002671","citation_count":52,"is_preprint":false},{"pmid":"19239915","id":"PMC_19239915","title":"The FAAH inhibitor URB-597 interferes with cisplatin- and nicotine-induced vomiting in the Suncus murinus (house musk shrew).","date":"2009","source":"Physiology & behavior","url":"https://pubmed.ncbi.nlm.nih.gov/19239915","citation_count":52,"is_preprint":false},{"pmid":"24460851","id":"PMC_24460851","title":"Selective inhibition of FAAH produces antidiarrheal and antinociceptive effect mediated by endocannabinoids and cannabinoid-like fatty acid amides.","date":"2013","source":"Neurogastroenterology and motility","url":"https://pubmed.ncbi.nlm.nih.gov/24460851","citation_count":52,"is_preprint":false},{"pmid":"26398331","id":"PMC_26398331","title":"Actions of the dual FAAH/MAGL inhibitor JZL195 in a murine neuropathic pain model.","date":"2015","source":"British journal of pharmacology","url":"https://pubmed.ncbi.nlm.nih.gov/26398331","citation_count":51,"is_preprint":false},{"pmid":"24384256","id":"PMC_24384256","title":"Actions of the dual FAAH/MAGL inhibitor JZL195 in a murine inflammatory pain model.","date":"2013","source":"Neuropharmacology","url":"https://pubmed.ncbi.nlm.nih.gov/24384256","citation_count":50,"is_preprint":false},{"pmid":"24083878","id":"PMC_24083878","title":"Chiral 1,3,4-oxadiazol-2-ones as highly selective FAAH inhibitors.","date":"2013","source":"Journal of medicinal chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/24083878","citation_count":50,"is_preprint":false},{"pmid":"17111174","id":"PMC_17111174","title":"Effects of the FAAH inhibitor, URB597, and anandamide on lithium-induced taste reactivity responses: a measure of nausea in the rat.","date":"2006","source":"Psychopharmacology","url":"https://pubmed.ncbi.nlm.nih.gov/17111174","citation_count":49,"is_preprint":false},{"pmid":"26713105","id":"PMC_26713105","title":"Preclinical Characterization of the FAAH Inhibitor JNJ-42165279.","date":"2015","source":"ACS medicinal chemistry letters","url":"https://pubmed.ncbi.nlm.nih.gov/26713105","citation_count":48,"is_preprint":false},{"pmid":"31379583","id":"PMC_31379583","title":"A New Use for an Old Drug: Carmofur Attenuates Lipopolysaccharide (LPS)-Induced Acute Lung Injury via Inhibition of FAAH and NAAA Activities.","date":"2019","source":"Frontiers in pharmacology","url":"https://pubmed.ncbi.nlm.nih.gov/31379583","citation_count":44,"is_preprint":false},{"pmid":"28730283","id":"PMC_28730283","title":"Blockade of alcohol escalation and \"relapse\" drinking by pharmacological FAAH inhibition in male and female C57BL/6J mice.","date":"2017","source":"Psychopharmacology","url":"https://pubmed.ncbi.nlm.nih.gov/28730283","citation_count":43,"is_preprint":false},{"pmid":"27327245","id":"PMC_27327245","title":"Fatty acid amide hydrolase (FAAH) blockade ameliorates experimental colitis by altering microRNA expression and suppressing inflammation.","date":"2016","source":"Brain, behavior, and immunity","url":"https://pubmed.ncbi.nlm.nih.gov/27327245","citation_count":43,"is_preprint":false},{"pmid":"12744923","id":"PMC_12744923","title":"Identification of the CB1 cannabinoid receptor and fatty acid amide hydrolase (FAAH) in the human placenta.","date":"2003","source":"Placenta","url":"https://pubmed.ncbi.nlm.nih.gov/12744923","citation_count":40,"is_preprint":false},{"pmid":"25058512","id":"PMC_25058512","title":"Combined inhibition of FAAH and COX produces enhanced anti-allodynic effects in mouse neuropathic and inflammatory pain models.","date":"2014","source":"Pharmacology, biochemistry, and behavior","url":"https://pubmed.ncbi.nlm.nih.gov/25058512","citation_count":40,"is_preprint":false},{"pmid":"25870539","id":"PMC_25870539","title":"Pharmacological blockade of the fatty acid amide hydrolase (FAAH) alters neural proliferation, apoptosis and gliosis in the rat hippocampus, hypothalamus and striatum in a negative energy context.","date":"2015","source":"Frontiers in cellular neuroscience","url":"https://pubmed.ncbi.nlm.nih.gov/25870539","citation_count":40,"is_preprint":false},{"pmid":"31335650","id":"PMC_31335650","title":"OPRM1 rs1799971, COMT rs4680, and FAAH rs324420 genes interact with placebo procedures to induce hypoalgesia.","date":"2019","source":"Pain","url":"https://pubmed.ncbi.nlm.nih.gov/31335650","citation_count":39,"is_preprint":false},{"pmid":"25910421","id":"PMC_25910421","title":"Inhibition of FAAH reduces nitroglycerin-induced migraine-like pain and trigeminal neuronal hyperactivity in mice.","date":"2015","source":"European neuropsychopharmacology : the journal of the European College of Neuropsychopharmacology","url":"https://pubmed.ncbi.nlm.nih.gov/25910421","citation_count":39,"is_preprint":false},{"pmid":"33129939","id":"PMC_33129939","title":"Characterization of the peripheral FAAH inhibitor, URB937, in animal models of acute and chronic migraine.","date":"2020","source":"Neurobiology of disease","url":"https://pubmed.ncbi.nlm.nih.gov/33129939","citation_count":39,"is_preprint":false},{"pmid":"28894217","id":"PMC_28894217","title":"The FAAH inhibitor URB597 suppresses hippocampal maximal dentate afterdischarges and restores seizure-induced impairment of short and long-term synaptic plasticity.","date":"2017","source":"Scientific reports","url":"https://pubmed.ncbi.nlm.nih.gov/28894217","citation_count":38,"is_preprint":false},{"pmid":"30159798","id":"PMC_30159798","title":"Inhibitions of anandamide transport and FAAH synthesis decrease apoptosis and oxidative stress through inhibition of TRPV1 channel in an in vitro seizure model.","date":"2018","source":"Molecular and cellular biochemistry","url":"https://pubmed.ncbi.nlm.nih.gov/30159798","citation_count":37,"is_preprint":false},{"pmid":"24215562","id":"PMC_24215562","title":"Membrane lipids are key modulators of the endocannabinoid-hydrolase FAAH.","date":"2014","source":"The Biochemical journal","url":"https://pubmed.ncbi.nlm.nih.gov/24215562","citation_count":36,"is_preprint":false},{"pmid":"32041998","id":"PMC_32041998","title":"The endocannabinoid hydrolase FAAH is an allosteric enzyme.","date":"2020","source":"Scientific reports","url":"https://pubmed.ncbi.nlm.nih.gov/32041998","citation_count":35,"is_preprint":false},{"pmid":"20010914","id":"PMC_20010914","title":"Association of polymorphisms of the cannabinoid receptor (CNR1) and fatty acid amide hydrolase (FAAH) genes with heroin addiction: impact of long repeats of CNR1.","date":"2009","source":"The pharmacogenomics journal","url":"https://pubmed.ncbi.nlm.nih.gov/20010914","citation_count":35,"is_preprint":false},{"pmid":"29967158","id":"PMC_29967158","title":"Role for fatty acid amide hydrolase (FAAH) in the leptin-mediated effects on feeding and energy balance.","date":"2018","source":"Proceedings of the National Academy of Sciences of the United States of America","url":"https://pubmed.ncbi.nlm.nih.gov/29967158","citation_count":33,"is_preprint":false},{"pmid":"30098312","id":"PMC_30098312","title":"Pharmacological blockade of fatty acid amide hydrolase (FAAH) by URB597 improves memory and changes the phenotype of hippocampal microglia despite ethanol exposure.","date":"2018","source":"Biochemical pharmacology","url":"https://pubmed.ncbi.nlm.nih.gov/30098312","citation_count":33,"is_preprint":false},{"pmid":"34685523","id":"PMC_34685523","title":"Dual Inhibition of FAAH and MAGL Counteracts Migraine-like Pain and Behavior in an Animal Model of Migraine.","date":"2021","source":"Cells","url":"https://pubmed.ncbi.nlm.nih.gov/34685523","citation_count":32,"is_preprint":false},{"pmid":"26561012","id":"PMC_26561012","title":"Circulating Endocannabinoids and the Polymorphism 385C>A in Fatty Acid Amide Hydrolase (FAAH) Gene May Identify the Obesity Phenotype Related to Cardiometabolic Risk: A Study Conducted in a Brazilian Population of Complex Interethnic Admixture.","date":"2015","source":"PloS one","url":"https://pubmed.ncbi.nlm.nih.gov/26561012","citation_count":32,"is_preprint":false},{"pmid":"19165169","id":"PMC_19165169","title":"Variants in the CNR1 and the FAAH genes and adiposity traits in the community.","date":"2009","source":"Obesity (Silver Spring, Md.)","url":"https://pubmed.ncbi.nlm.nih.gov/19165169","citation_count":31,"is_preprint":false},{"pmid":"20631561","id":"PMC_20631561","title":"Endocannabinoid Pro129Thr FAAH functional polymorphism but not 1359G/A CNR1 polymorphism is associated with antipsychotic-induced weight gain.","date":"2010","source":"Journal of clinical psychopharmacology","url":"https://pubmed.ncbi.nlm.nih.gov/20631561","citation_count":31,"is_preprint":false},{"pmid":"34587978","id":"PMC_34587978","title":"Potentiation of amyloid beta phagocytosis and amelioration of synaptic dysfunction upon FAAH deletion in a mouse model of Alzheimer's disease.","date":"2021","source":"Journal of neuroinflammation","url":"https://pubmed.ncbi.nlm.nih.gov/34587978","citation_count":31,"is_preprint":false},{"pmid":"24900385","id":"PMC_24900385","title":"Aryl Piperazinyl Ureas as Inhibitors of Fatty Acid Amide Hydrolase (FAAH) in Rat, Dog, and Primate.","date":"2012","source":"ACS medicinal chemistry letters","url":"https://pubmed.ncbi.nlm.nih.gov/24900385","citation_count":30,"is_preprint":false},{"pmid":"34299330","id":"PMC_34299330","title":"Fatty Acid Amide Hydrolase (FAAH) Inhibition Modulates Amyloid-Beta-Induced Microglia Polarization.","date":"2021","source":"International journal of molecular sciences","url":"https://pubmed.ncbi.nlm.nih.gov/34299330","citation_count":30,"is_preprint":false},{"pmid":"34968475","id":"PMC_34968475","title":"Role of PI3K/Akt axis in mitigating hippocampal ischemia-reperfusion injury via CB1 receptor stimulation by paracetamol and FAAH inhibitor in rat.","date":"2021","source":"Neuropharmacology","url":"https://pubmed.ncbi.nlm.nih.gov/34968475","citation_count":30,"is_preprint":false},{"pmid":"32488870","id":"PMC_32488870","title":"Impacts of epidural electrical stimulation on Wnt signaling, FAAH, and BDNF following thoracic spinal cord injury in rat.","date":"2020","source":"Journal of cellular physiology","url":"https://pubmed.ncbi.nlm.nih.gov/32488870","citation_count":30,"is_preprint":false},{"pmid":"28850633","id":"PMC_28850633","title":"Fatty acid amide hydrolase (FAAH) inhibitor PF-3845 reduces viability, migration and invasiveness of human colon adenocarcinoma Colo-205 cell line: an in vitro study.","date":"2017","source":"Acta biochimica Polonica","url":"https://pubmed.ncbi.nlm.nih.gov/28850633","citation_count":29,"is_preprint":false},{"pmid":"24275607","id":"PMC_24275607","title":"Inhibition of fatty acid amide hydrolase (FAAH) as a novel therapeutic strategy in the treatment of pain and inflammatory diseases in the gastrointestinal tract.","date":"2013","source":"European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences","url":"https://pubmed.ncbi.nlm.nih.gov/24275607","citation_count":29,"is_preprint":false},{"pmid":"26360704","id":"PMC_26360704","title":"Potential Therapeutic Value of a Novel FAAH Inhibitor for the Treatment of Anxiety.","date":"2015","source":"PloS one","url":"https://pubmed.ncbi.nlm.nih.gov/26360704","citation_count":29,"is_preprint":false},{"pmid":"24746881","id":"PMC_24746881","title":"Inhibition of peripheral FAAH depresses activities of bladder mechanosensitive nerve fibers of the rat.","date":"2014","source":"The Journal of urology","url":"https://pubmed.ncbi.nlm.nih.gov/24746881","citation_count":28,"is_preprint":false},{"pmid":"21442624","id":"PMC_21442624","title":"Hyperglycemia induces apoptosis via CB1 activation through the decrease of FAAH 1 in retinal pigment epithelial cells.","date":"2012","source":"Journal of cellular physiology","url":"https://pubmed.ncbi.nlm.nih.gov/21442624","citation_count":28,"is_preprint":false},{"pmid":"33530477","id":"PMC_33530477","title":"Distinct Activity of Endocannabinoid-Hydrolyzing Enzymes MAGL and FAAH in Key Regions of Peripheral and Central Nervous System Implicated in Migraine.","date":"2021","source":"International journal of molecular sciences","url":"https://pubmed.ncbi.nlm.nih.gov/33530477","citation_count":27,"is_preprint":false},{"pmid":"28583049","id":"PMC_28583049","title":"N-arachidonoyl-serotonin, a dual FAAH and TRPV1 blocker, inhibits the retrieval of contextual fear memory: Role of the cannabinoid CB1 receptor in the dorsal hippocampus.","date":"2017","source":"Journal of psychopharmacology (Oxford, England)","url":"https://pubmed.ncbi.nlm.nih.gov/28583049","citation_count":27,"is_preprint":false},{"pmid":"22442717","id":"PMC_22442717","title":"Peripheral effects of FAAH deficiency on fuel and energy homeostasis: role of dysregulated lysine acetylation.","date":"2012","source":"PloS one","url":"https://pubmed.ncbi.nlm.nih.gov/22442717","citation_count":27,"is_preprint":false},{"pmid":"23853040","id":"PMC_23853040","title":"The macamide N-3-methoxybenzyl-linoleamide is a time-dependent fatty acid amide hydrolase (FAAH) inhibitor.","date":"2013","source":"Molecular neurobiology","url":"https://pubmed.ncbi.nlm.nih.gov/23853040","citation_count":27,"is_preprint":false},{"pmid":"28237711","id":"PMC_28237711","title":"Pharmacological inhibition of FAAH modulates TLR-induced neuroinflammation, but not sickness behaviour: An effect partially mediated by central TRPV1.","date":"2017","source":"Brain, behavior, and immunity","url":"https://pubmed.ncbi.nlm.nih.gov/28237711","citation_count":27,"is_preprint":false},{"pmid":"29953903","id":"PMC_29953903","title":"FAAH inhibition attenuates TLR3-mediated hyperthermia, nociceptive- and anxiety-like behaviour in female rats.","date":"2018","source":"Behavioural brain research","url":"https://pubmed.ncbi.nlm.nih.gov/29953903","citation_count":26,"is_preprint":false},{"pmid":"17686199","id":"PMC_17686199","title":"Vanilloid receptor 1 (TRPV1/VR1) co-localizes with fatty acid amide hydrolase (FAAH) in retinal amacrine cells.","date":"2007","source":"Visual neuroscience","url":"https://pubmed.ncbi.nlm.nih.gov/17686199","citation_count":26,"is_preprint":false},{"pmid":"25041240","id":"PMC_25041240","title":"Endocannabinoid modulation by FAAH and monoacylglycerol lipase within the analgesic circuitry of the periaqueductal grey.","date":"2014","source":"British journal of pharmacology","url":"https://pubmed.ncbi.nlm.nih.gov/25041240","citation_count":26,"is_preprint":false},{"pmid":"25558980","id":"PMC_25558980","title":"Novel associations between FAAH genetic variants and postoperative central opioid-related adverse effects.","date":"2015","source":"The pharmacogenomics journal","url":"https://pubmed.ncbi.nlm.nih.gov/25558980","citation_count":26,"is_preprint":false},{"pmid":"26558620","id":"PMC_26558620","title":"Effects of fatty acid amide hydrolase (FAAH) inhibitors on working memory in rats.","date":"2015","source":"Psychopharmacology","url":"https://pubmed.ncbi.nlm.nih.gov/26558620","citation_count":26,"is_preprint":false},{"pmid":"23455058","id":"PMC_23455058","title":"(4-Phenoxyphenyl)tetrazolecarboxamides and related compounds as dual inhibitors of fatty acid amide hydrolase (FAAH) and monoacylglycerol lipase (MAGL).","date":"2013","source":"European journal of medicinal chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/23455058","citation_count":25,"is_preprint":false},{"pmid":"25283614","id":"PMC_25283614","title":"Correlating FAAH and anandamide cellular uptake inhibition using N-alkylcarbamate inhibitors: from ultrapotent to hyperpotent.","date":"2014","source":"Biochemical pharmacology","url":"https://pubmed.ncbi.nlm.nih.gov/25283614","citation_count":25,"is_preprint":false},{"pmid":"27938441","id":"PMC_27938441","title":"A dual inhibitor of FAAH and TRPV1 channels shows dose-dependent effect on depression-like behaviour in rats.","date":"2016","source":"Acta neuropsychiatrica","url":"https://pubmed.ncbi.nlm.nih.gov/27938441","citation_count":25,"is_preprint":false},{"pmid":"30291441","id":"PMC_30291441","title":"Impact of FAAH genetic variation on fronto-amygdala function during emotional processing.","date":"2018","source":"European archives of psychiatry and clinical neuroscience","url":"https://pubmed.ncbi.nlm.nih.gov/30291441","citation_count":25,"is_preprint":false},{"pmid":"18805581","id":"PMC_18805581","title":"Nuclear localisation of the endocannabinoid metabolizing enzyme fatty acid amide hydrolase (FAAH) in invasive trophoblasts and an association with recurrent miscarriage.","date":"2008","source":"Placenta","url":"https://pubmed.ncbi.nlm.nih.gov/18805581","citation_count":25,"is_preprint":false},{"pmid":"31948828","id":"PMC_31948828","title":"Antidepressant-like effects of pharmacological inhibition of FAAH activity in socially isolated female rats.","date":"2020","source":"European neuropsychopharmacology : the journal of the European College of Neuropsychopharmacology","url":"https://pubmed.ncbi.nlm.nih.gov/31948828","citation_count":24,"is_preprint":false},{"pmid":"24223930","id":"PMC_24223930","title":"Role of FAAH-like anandamide transporter in anandamide inactivation.","date":"2013","source":"PloS one","url":"https://pubmed.ncbi.nlm.nih.gov/24223930","citation_count":23,"is_preprint":false},{"pmid":"33736974","id":"PMC_33736974","title":"GPR18 drives FAAH inhibition-induced neuroprotection against HIV-1 Tat-induced neurodegeneration.","date":"2021","source":"Experimental neurology","url":"https://pubmed.ncbi.nlm.nih.gov/33736974","citation_count":22,"is_preprint":false},{"pmid":"20054193","id":"PMC_20054193","title":"Evaluating the association of FAAH common gene variation with childhood, adult severe obesity and type 2 diabetes in the French population.","date":"2008","source":"Obesity facts","url":"https://pubmed.ncbi.nlm.nih.gov/20054193","citation_count":22,"is_preprint":false},{"pmid":"20056290","id":"PMC_20056290","title":"C358A missense polymorphism of the endocannabinoid degrading enzyme fatty acid amide hydrolase (FAAH) and insulin resistance in patients with diabetes mellitus type 2.","date":"2010","source":"Diabetes research and clinical practice","url":"https://pubmed.ncbi.nlm.nih.gov/20056290","citation_count":22,"is_preprint":false},{"pmid":"34093011","id":"PMC_34093011","title":"Neuroprotective Effects of VEGF-A Nanofiber Membrane and FAAH Inhibitor URB597 Against Oxygen-Glucose Deprivation-Induced Ischemic Neuronal Injury.","date":"2021","source":"International journal of nanomedicine","url":"https://pubmed.ncbi.nlm.nih.gov/34093011","citation_count":21,"is_preprint":false},{"pmid":"34217798","id":"PMC_34217798","title":"The role of endocannabinoid pathway in the neuropathology of Alzheimer's disease: Can the inhibitors of MAGL and FAAH prove to be potential therapeutic targets against the cognitive impairment associated with Alzheimer's disease?","date":"2021","source":"Brain research bulletin","url":"https://pubmed.ncbi.nlm.nih.gov/34217798","citation_count":21,"is_preprint":false},{"pmid":"30380982","id":"PMC_30380982","title":"Analgesic effects of FAAH inhibitor in the insular cortex of nerve-injured rats.","date":"2018","source":"Molecular pain","url":"https://pubmed.ncbi.nlm.nih.gov/30380982","citation_count":21,"is_preprint":false},{"pmid":"36083191","id":"PMC_36083191","title":"Activity-based Photoacoustic Probes Reveal Elevated Intestinal MGL and FAAH Activity in a Murine Model of Obesity.","date":"2022","source":"Angewandte Chemie (International ed. in English)","url":"https://pubmed.ncbi.nlm.nih.gov/36083191","citation_count":21,"is_preprint":false},{"pmid":"29926378","id":"PMC_29926378","title":"Inhibition of Fatty Acid Amide Hydrolase (FAAH) by Macamides.","date":"2018","source":"Molecular neurobiology","url":"https://pubmed.ncbi.nlm.nih.gov/29926378","citation_count":21,"is_preprint":false},{"pmid":"36555739","id":"PMC_36555739","title":"FAAH Inhibition Restores Early Life Stress-Induced Alterations in PFC microRNAs Associated with Depressive-Like Behavior in Male and Female Rats.","date":"2022","source":"International journal of molecular sciences","url":"https://pubmed.ncbi.nlm.nih.gov/36555739","citation_count":21,"is_preprint":false},{"pmid":"24102214","id":"PMC_24102214","title":"Prostamide F(2) α receptor antagonism combined with inhibition of FAAH may block the pro-inflammatory mediators formed following selective FAAH inhibition.","date":"2014","source":"British journal of pharmacology","url":"https://pubmed.ncbi.nlm.nih.gov/24102214","citation_count":20,"is_preprint":false}],"cost":{"stage1":{"model":"claude-sonnet-4-6","input_tokens":53350,"output_tokens":4583,"usd":0.114397},"stage2":{"model":"claude-opus-4-6","input_tokens":8055,"output_tokens":3143,"usd":0.178275},"total_usd":0.292672,"stage1_batch_id":"msgbatch_0118RScg3WGaGkaZRtWZbtce","stage2_batch_id":"msgbatch_01Cpfzvtbj42aqp5oYZ5Te2s","note":"batch pricing = 50% of standard"},"stage1_raw":"```json\n{\n  \"discoveries\": [\n    {\n      \"year\": 2009,\n      \"finding\": \"PF-3845 is a covalent FAAH inhibitor that carbamylates the active-site serine nucleophile of FAAH, as confirmed by mechanistic and structural studies. It selectively inhibits FAAH in vivo (verified by activity-based protein profiling), raises brain anandamide levels for up to 24 hours, and produces CB1 receptor-dependent reductions in inflammatory pain.\",\n      \"method\": \"Mechanistic studies (active-site carbamylation), structural studies, activity-based protein profiling, in vivo pharmacology with CB1 antagonist\",\n      \"journal\": \"Chemistry & biology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 — covalent mechanism confirmed by structural and mechanistic studies with multiple orthogonal methods in a single study\",\n      \"pmids\": [\"19389627\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2008,\n      \"finding\": \"Crystal structure of humanized rat FAAH (h/rFAAH) complexed with inhibitor PF-750 at 2.75-Å resolution revealed the structural basis for species selectivity of FAAH inhibitors. The active sites of rat and human FAAH were interconverted by site-directed mutagenesis, producing a protein with human FAAH inhibitor-sensitivity but rat FAAH expression yield.\",\n      \"method\": \"X-ray crystallography, site-directed mutagenesis, inhibitor profiling\",\n      \"journal\": \"Proceedings of the National Academy of Sciences of the United States of America\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 — crystal structure with functional mutagenesis validation\",\n      \"pmids\": [\"18753625\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2011,\n      \"finding\": \"PF-04457845 inhibits FAAH by a covalent, irreversible mechanism involving carbamylation of the active-site serine nucleophile (kinact/Ki = 40,300 M⁻¹s⁻¹; IC50 = 7.2 nM for human FAAH), with exquisite selectivity over other serine hydrolases as demonstrated by competitive activity-based protein profiling.\",\n      \"method\": \"In vitro enzyme kinetics, active-site carbamylation mechanism, competitive activity-based protein profiling\",\n      \"journal\": \"ACS medicinal chemistry letters\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 — covalent catalytic mechanism confirmed by kinetics and ABPP selectivity profiling\",\n      \"pmids\": [\"21666860\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2000,\n      \"finding\": \"FAAH is a serine hydrolase containing an amidase domain with a serine catalytic nucleophile responsible for hydrolysis of anandamide and related fatty acid amides. Conserved domains include a hydrophobic domain important for self-association and a proline-rich domain potentially important for subcellular localization. Recombinant FAAH was purified and characterized following cloning from rat, mouse, human, and pig.\",\n      \"method\": \"cDNA cloning, recombinant protein purification, domain mutagenesis/sequence analysis, enzyme activity assays\",\n      \"journal\": \"Chemistry and physics of lipids\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 — foundational cloning and biochemical characterization replicated across multiple species\",\n      \"pmids\": [\"11106785\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2011,\n      \"finding\": \"A catalytically silent splice variant of FAAH-1 (termed FLAT, FAAH-like anandamide transporter) lacked amidase activity but bound anandamide with low micromolar affinity and facilitated its translocation into cells, identifying it as a molecular component of anandamide transport in neural cells. Known anandamide transport inhibitors (AM404, OMDM-1) blocked these effects.\",\n      \"method\": \"Molecular cloning, binding assays, cellular uptake assays, pharmacological inhibition, in vivo antinociceptive studies\",\n      \"journal\": \"Nature neuroscience\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — multiple in vitro and in vivo methods but disputed by follow-up study (PMID:24223930)\",\n      \"pmids\": [\"22101642\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2013,\n      \"finding\": \"A follow-up study found that FLAT displayed residual catalytic activity sensitive to FAAH inhibitors and abolished by mutation of its catalytic serine; overexpression of FLAT potentiated AEA cellular uptake in a manner dependent on its catalytic activity rather than transport function. FLAT was not detected in multiple tissues examined, suggesting it does not serve as a global intracellular AEA carrier.\",\n      \"method\": \"PCR-based generation of FLAT construct, mutagenesis of catalytic serine, cellular uptake assays in FAAH-expressing and FAAH-deficient cells, immunofluorescence localization\",\n      \"journal\": \"PloS one\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — mutagenesis and multiple cell-based assays, but contradicts the original FLAT characterization\",\n      \"pmids\": [\"24223930\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2014,\n      \"finding\": \"Membrane lipid composition modulates FAAH structure, subcellular localization, and activity. The FAAH dimer is stabilized by the lipid bilayer, shows higher membrane-binding affinity and enzymatic activity in membranes containing both cholesterol and the substrate anandamide (AEA). Co-localization of cholesterol, AEA, and FAAH in mouse neuroblastoma cells suggests cholesterol increases FAAH substrate accessibility.\",\n      \"method\": \"Combined experimental (enzyme activity assays, co-localization imaging) and computational (molecular dynamics simulation) approach\",\n      \"journal\": \"The Biochemical journal\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — multiple orthogonal methods (biochemical + computational + cell imaging) from a single study\",\n      \"pmids\": [\"24215562\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2020,\n      \"finding\": \"FAAH is an allosteric homodimeric enzyme: occupation of only one of the two active sites is sufficient to fully block catalysis. A single W445Y substitution eliminated allostery (Hill coefficient ~1.0) without reducing activity, while F432A reduced specific activity but retained allostery. Human FAAH also showed allosteric AEA hydrolysis (Hill coefficient ~1.9), implicating W445 at the dimer interface as a key allosteric residue.\",\n      \"method\": \"Site-directed mutagenesis, enzyme kinetics (Hill coefficient analysis), stoichiometric inhibitor titration of human and rat FAAH\",\n      \"journal\": \"Scientific reports\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 — reconstituted kinetic analysis with mutagenesis of specific residues in both human and rat FAAH\",\n      \"pmids\": [\"32041998\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2003,\n      \"finding\": \"Progesterone activates the FAAH promoter in human T lymphocytes through the transcription factor Ikaros. Mutation of Ikaros binding sites (ERE2/3) in the FAAH promoter prevented progesterone-induced FAAH transcription. Leptin additively activates FAAH expression via a cAMP response element-like site. Progesterone-induced FAAH upregulation decreased cellular anandamide levels.\",\n      \"method\": \"Transient expression/reporter assays, EMSA and supershift assays, site-directed mutagenesis of promoter, enzyme activity assays\",\n      \"journal\": \"The Journal of biological chemistry\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1/2 — promoter mutagenesis, EMSA, and functional reporter assays with multiple orthogonal methods\",\n      \"pmids\": [\"12799380\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2012,\n      \"finding\": \"Estrogen (E2) directly induces FAAH transcription in mouse Sertoli cells via estrogen receptor β binding to two proximal ERE sequences (ERE2/3) in the faah promoter. The histone demethylase LSD1 is associated with these sites and mediates E2 induction of FAAH expression. E2 induced epigenetic modifications (decreased DNA methylation at CpG and H3K9 methylation) compatible with transcriptional activation. FAAH silencing abolished E2-mediated protection against anandamide-induced apoptosis.\",\n      \"method\": \"Luciferase reporter assays, promoter mutagenesis, ChIP, bisulfite methylation analysis, FAAH siRNA knockdown, apoptosis assays\",\n      \"journal\": \"Cellular and molecular life sciences : CMLS\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1/2 — multiple orthogonal methods including ChIP, mutagenesis, and functional rescue experiments\",\n      \"pmids\": [\"22802127\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2017,\n      \"finding\": \"Activity-based proteomic profiling of the FAAH inhibitor BIA 10-2474 in human cells and tissues revealed that it inhibits several lipases beyond FAAH that are not targeted by the selective inhibitor PF04457845. BIA 10-2474, but not PF04457845, produced substantial alterations in lipid networks in human cortical neurons, indicating that promiscuous lipase inhibition causes metabolic dysregulation in the nervous system.\",\n      \"method\": \"Activity-based protein profiling (ABPP) in human cells/tissues, lipid network analysis in human cortical neurons\",\n      \"journal\": \"Science (New York, N.Y.)\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1/2 — systematic proteome-wide ABPP combined with lipidomics in human tissue; high citation count\",\n      \"pmids\": [\"28596366\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2015,\n      \"finding\": \"The common human FAAH C385A polymorphism (rs324420) reduces FAAH expression and activity, thereby increasing anandamide levels. Knock-in mice recapitulating this variant showed selectively enhanced fronto-amygdala connectivity, facilitated fear extinction learning, and decreased anxiety-like behaviors, paralleling effects in human A-allele carriers.\",\n      \"method\": \"Knock-in mouse generation, FAAH activity and expression assays, behavioral testing, neuroimaging (fMRI connectivity), parallel human genetics analysis\",\n      \"journal\": \"Nature communications\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — translational knock-in model with biochemical, behavioral, and neuroimaging validation replicated in humans\",\n      \"pmids\": [\"25731744\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2018,\n      \"finding\": \"FAAH activity is required for leptin's hypophagic effects. Leptin-deficient mice showed elevated hypothalamic anandamide and reduced FAAH activity; leptin administration to WT mice reduced AEA and increased FAAH activity. FAAH C385A knock-in mice with reduced FAAH activity were unresponsive to leptin-induced reductions in food intake and body weight. Pharmacological FAAH inhibition was sufficient to prevent leptin-mediated changes in body weight and food intake.\",\n      \"method\": \"Leptin administration to WT/ob/ob mice (endocannabinoid measurement by mass spectrometry), FAAH C385A knock-in mice, FAAH inhibitor pharmacology, high-fat diet challenge\",\n      \"journal\": \"Proceedings of the National Academy of Sciences of the United States of America\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — multiple genetic and pharmacological approaches with biochemical endpoint measurements\",\n      \"pmids\": [\"29967158\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2012,\n      \"finding\": \"FAAH anti-allodynic effects in LPS-induced tactile allodynia are mediated specifically by neuronal FAAH: mice expressing FAAH exclusively in the nervous system (under neural specific enolase promoter) did not show the anti-allodynic phenotype of wild-type mice treated with FAAH inhibitors. The anti-allodynic effects required activation of both CB1 and CB2 receptors.\",\n      \"method\": \"Neuron-specific FAAH rescue mouse model, pharmacological inhibition (URB597, OL-135, PF-3845), endocannabinoid mass spectrometry, CB1/CB2 antagonist pharmacology\",\n      \"journal\": \"British journal of pharmacology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — genetic rescue model combined with pharmacological receptor characterization and biochemical measurements\",\n      \"pmids\": [\"21506952\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2014,\n      \"finding\": \"In the periaqueductal grey (PAG), anandamide (but not 2-AG) produced reduction of inhibitory GABAergic transmission via disinhibition. This AEA-induced suppression was enhanced by the FAAH inhibitor URB597, while 2-AG-induced suppression was unmasked only by the MAGL inhibitor JZL184. Combined FAAH/MAGL inhibition enhanced tonic disinhibition, consistent with analgesic action.\",\n      \"method\": \"In vitro electrophysiological recordings from rat midbrain PAG slices, cannabinoid receptor antagonist pharmacology\",\n      \"journal\": \"British journal of pharmacology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1/2 — in vitro electrophysiology with defined circuit-level mechanism and receptor pharmacology\",\n      \"pmids\": [\"25041240\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2008,\n      \"finding\": \"FAAH was unexpectedly localized to the nucleus of invasive extravillous trophoblasts in recurrent miscarriage cases (verified by western blotting of subcellular fractions and confocal microscopy), as opposed to cytoplasmic localization in normal pregnancies. FAAH was overexpressed in trophoblasts that had invaded the decidua in 67% of recurrent miscarriage cases but not in normal pregnancies.\",\n      \"method\": \"Immunohistochemistry, subcellular fractionation with western blotting, confocal microscopy\",\n      \"journal\": \"Placenta\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2/3 — subcellular localization confirmed by fractionation and confocal; functional significance not fully established\",\n      \"pmids\": [\"18805581\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2021,\n      \"finding\": \"FAAH genetic inactivation in the 5xFAD Alzheimer's disease mouse model rescued hippocampal synaptic plasticity (basal synaptic transmission and LTP at CA3-CA1 synapses) and restored dendritic spine density in CA1 pyramidal neurons. The LTP rescue was independent of CB1R and TRPV1 receptors. FAAH deletion upregulated microglial phagocytic factors (TREM2, CTSD) and amyloid beta clearance factors (complement C3, C3AR), potentiating amyloid beta phagocytosis.\",\n      \"method\": \"Electrophysiology (LTP recording), flow cytometry, dendritic spine morphometry, molecular analysis of microglial markers in 5xFAD/FAAH⁻/⁻ mice\",\n      \"journal\": \"Journal of neuroinflammation\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — multiple orthogonal methods (electrophysiology, morphometry, molecular) in a defined genetic model\",\n      \"pmids\": [\"34587978\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2012,\n      \"finding\": \"Hyperglycemia downregulates FAAH-1 expression in retinal pigment epithelial cells, leading to elevated anandamide and upregulated CB1 receptor expression. Overexpression of FAAH-1 blocked high-glucose-induced CB1R internalization, ROS generation, and apoptosis (reduced Bax/Bcl-2 ratio and caspase activation), establishing FAAH-1 as a regulator of CB1R-mediated apoptosis in diabetic retinopathy.\",\n      \"method\": \"Overexpression of FAAH-1, siRNA knockdown of CB1R, CB1R antagonist (AM251), ROS measurement, apoptosis assays (caspase-3/9, PARP cleavage, cell viability)\",\n      \"journal\": \"Journal of cellular physiology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — multiple loss/gain-of-function experiments with mechanistic biochemical readouts\",\n      \"pmids\": [\"21442624\"],\n      \"is_preprint\": false\n    }\n  ],\n  \"current_model\": \"FAAH is an integral membrane serine hydrolase that forms a homodimer and operates via an allosteric catalytic mechanism in which occupancy of one active-site serine nucleophile is sufficient to block both subunits; it degrades anandamide and related fatty acid amide signaling lipids by carbamylation/hydrolysis, with its activity modulated by membrane lipid composition (cholesterol), regulated transcriptionally by progesterone (via Ikaros), estrogen (via ERβ/LSD1), and leptin (via CRE-like elements), and positioned as the primary catabolic determinant of endocannabinoid tone in pain, anxiety, fear extinction, and metabolic signaling circuits.\"\n}\n```","stage2_raw":"```json\n{\n  \"mechanistic_narrative\": \"FAAH is an integral membrane serine hydrolase that degrades anandamide and related fatty acid amides, serving as the primary catabolic enzyme controlling endocannabinoid tone in the nervous system and peripheral tissues [PMID:11106785, PMID:19389627]. It functions as an allosteric homodimer in which occupation of a single active-site serine nucleophile is sufficient to block catalysis across both subunits, with tryptophan 445 at the dimer interface mediating inter-subunit communication [PMID:32041998]. FAAH activity is modulated by membrane cholesterol content, which enhances substrate accessibility and enzymatic activity [PMID:24215562], and its transcription is induced by progesterone (via Ikaros), estrogen (via ERβ/LSD1-mediated epigenetic remodeling), and leptin (via a CRE-like element) [PMID:12799380, PMID:22802127, PMID:29967158]. The common human C385A polymorphism reduces FAAH expression and elevates anandamide levels, enhancing fronto-amygdala connectivity, facilitating fear extinction, decreasing anxiety, and attenuating leptin-mediated hypophagia, establishing FAAH as a critical determinant of endocannabinoid signaling in pain, anxiety, metabolic regulation, and neuroinflammation [PMID:25731744, PMID:29967158, PMID:21506952, PMID:34587978].\",\n  \"teleology\": [\n    {\n      \"year\": 2000,\n      \"claim\": \"Identification of FAAH as a serine hydrolase with an amidase catalytic domain responsible for anandamide degradation established the molecular identity and enzymatic mechanism of the primary endocannabinoid-degrading enzyme.\",\n      \"evidence\": \"cDNA cloning from rat, mouse, human, and pig with recombinant protein purification and domain analysis\",\n      \"pmids\": [\"11106785\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"No high-resolution structure yet available\", \"Membrane topology and oligomeric state not resolved\", \"Physiological substrate hierarchy not defined\"]\n    },\n    {\n      \"year\": 2003,\n      \"claim\": \"Discovery that progesterone activates FAAH transcription through Ikaros binding to ERE2/3 sites, and leptin acts additively via a CRE-like element, revealed how hormonal signals control endocannabinoid tone by regulating FAAH expression.\",\n      \"evidence\": \"Promoter-reporter assays, EMSA/supershift, site-directed mutagenesis in human T lymphocytes\",\n      \"pmids\": [\"12799380\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Physiological relevance of Ikaros-mediated regulation in non-immune cells not tested\", \"Leptin-FAAH transcriptional pathway intermediates not fully mapped\"]\n    },\n    {\n      \"year\": 2008,\n      \"claim\": \"The crystal structure of humanized rat FAAH with an inhibitor revealed the structural basis for species-selective inhibitor binding and enabled rational drug design by interconverting rat and human active sites through mutagenesis.\",\n      \"evidence\": \"X-ray crystallography at 2.75 Å resolution with site-directed mutagenesis\",\n      \"pmids\": [\"18753625\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Full-length human FAAH structure not yet solved\", \"Membrane-embedded dimer structure unknown\"]\n    },\n    {\n      \"year\": 2009,\n      \"claim\": \"Demonstration that PF-3845 covalently carbamylates the FAAH active-site serine, selectively raises brain anandamide for 24 hours, and produces CB1-dependent analgesia established the in vivo proof-of-concept that selective FAAH inhibition modulates endocannabinoid signaling to reduce pain.\",\n      \"evidence\": \"Structural/mechanistic studies, activity-based protein profiling, in vivo pharmacology with CB1 antagonist\",\n      \"pmids\": [\"19389627\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Contribution of non-anandamide FAAH substrates to analgesic effect unclear\", \"Long-term consequences of sustained FAAH inhibition not assessed\"]\n    },\n    {\n      \"year\": 2012,\n      \"claim\": \"Estrogen was shown to induce FAAH transcription via ERβ binding to proximal ERE sites with recruitment of the histone demethylase LSD1, causing epigenetic remodeling that protects Sertoli cells from anandamide-induced apoptosis, broadening the hormonal control of FAAH to include estrogen-dependent epigenetic mechanisms.\",\n      \"evidence\": \"ChIP, luciferase reporters, promoter mutagenesis, bisulfite methylation, FAAH siRNA knockdown, apoptosis assays in mouse Sertoli cells\",\n      \"pmids\": [\"22802127\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Whether ERβ/LSD1-mediated regulation operates in neural tissues not tested\", \"Interplay between progesterone/Ikaros and estrogen/ERβ pathways not examined\"]\n    },\n    {\n      \"year\": 2012,\n      \"claim\": \"Tissue-specific FAAH rescue experiments showed that non-neuronal FAAH is required for anti-allodynic effects of FAAH inhibitors in inflammatory pain, acting through both CB1 and CB2 receptors, clarifying that peripheral endocannabinoid metabolism is a key analgesic site.\",\n      \"evidence\": \"Neuron-specific FAAH rescue mouse model, pharmacological inhibition, CB1/CB2 antagonists, endocannabinoid mass spectrometry\",\n      \"pmids\": [\"21506952\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Specific peripheral cell type(s) responsible not identified\", \"Relative contribution of peripheral vs. central FAAH in chronic pain models unknown\"]\n    },\n    {\n      \"year\": 2014,\n      \"claim\": \"Cholesterol was found to enhance FAAH membrane binding affinity, dimer stability, and enzymatic activity, with co-localization of cholesterol, anandamide, and FAAH in neuroblastoma cells, establishing membrane lipid composition as a regulator of FAAH catalysis.\",\n      \"evidence\": \"Combined enzyme activity assays, co-localization imaging, and molecular dynamics simulation in mouse neuroblastoma cells\",\n      \"pmids\": [\"24215562\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"In vivo validation of cholesterol-dependent activity modulation not performed\", \"Whether cholesterol acts by altering substrate presentation vs. direct protein interaction not resolved\"]\n    },\n    {\n      \"year\": 2015,\n      \"claim\": \"The human FAAH C385A polymorphism was shown via knock-in mice to reduce FAAH expression and activity, elevate anandamide, enhance fronto-amygdala connectivity, and facilitate fear extinction, directly linking FAAH genetic variation to anxiety and emotional learning circuits.\",\n      \"evidence\": \"Knock-in mouse generation, FAAH activity assays, behavioral testing, fMRI connectivity, parallel human genotype-phenotype analysis\",\n      \"pmids\": [\"25731744\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Downstream signaling mediators of enhanced fear extinction not identified\", \"Whether effects are fully CB1-dependent not tested\"]\n    },\n    {\n      \"year\": 2017,\n      \"claim\": \"Proteome-wide activity profiling revealed that the clinical FAAH inhibitor BIA 10-2474 inhibited multiple off-target lipases, causing lipid network dysregulation in human cortical neurons, while the selective inhibitor PF04457845 did not—clarifying that toxicity in the BIA 10-2474 trial arose from off-target effects rather than FAAH inhibition per se.\",\n      \"evidence\": \"Activity-based protein profiling in human cells and tissues, lipidomics in human cortical neurons\",\n      \"pmids\": [\"28596366\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Complete target list of BIA 10-2474 metabolites not characterized\", \"Whether any FAAH-dependent lipid changes contribute to neurotoxicity not excluded\"]\n    },\n    {\n      \"year\": 2018,\n      \"claim\": \"FAAH was established as a required effector of leptin's hypophagic action: leptin increases hypothalamic FAAH activity to reduce anandamide, and C385A knock-in mice or pharmacological FAAH inhibition abolished leptin-induced reductions in food intake and body weight.\",\n      \"evidence\": \"Leptin administration in WT/ob/ob mice, endocannabinoid mass spectrometry, FAAH C385A knock-in mice, FAAH inhibitor pharmacology\",\n      \"pmids\": [\"29967158\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Transcriptional vs. post-translational mechanism of leptin-induced FAAH activation not distinguished in vivo\", \"Whether other FAAH substrates beyond AEA contribute to metabolic effects unknown\"]\n    },\n    {\n      \"year\": 2020,\n      \"claim\": \"Kinetic analysis revealed FAAH operates as an allosteric homodimer where occupation of one active site blocks both subunits, with W445 at the dimer interface mediating inter-subunit communication, fundamentally redefining the stoichiometry of FAAH inhibition.\",\n      \"evidence\": \"Hill coefficient analysis, stoichiometric inhibitor titration, site-directed mutagenesis (W445Y, F432A) of human and rat FAAH\",\n      \"pmids\": [\"32041998\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Structural basis for allosteric communication not determined at atomic level\", \"Whether allostery is substrate-dependent not tested\", \"In vivo relevance of half-site inhibition not demonstrated\"]\n    },\n    {\n      \"year\": 2021,\n      \"claim\": \"FAAH genetic deletion rescued hippocampal synaptic plasticity and dendritic spine density in an Alzheimer's model via a CB1R/TRPV1-independent mechanism involving upregulation of microglial phagocytic and amyloid-clearance pathways, extending FAAH function to neuroinflammation and neurodegeneration.\",\n      \"evidence\": \"Electrophysiology, dendritic spine morphometry, flow cytometry, and molecular analysis in 5xFAD/FAAH−/− mice\",\n      \"pmids\": [\"34587978\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Identity of the FAAH-derived lipid mediator(s) responsible for microglial activation unknown\", \"CB1R/TRPV1-independent mechanism not molecularly defined\", \"Replication in independent AD models needed\"]\n    },\n    {\n      \"year\": null,\n      \"claim\": \"The structural basis for FAAH allosteric communication across the dimer interface, the identity of FAAH substrates beyond anandamide that drive its metabolic and neuroinflammatory functions, and the mechanism by which FAAH loss activates microglial phagocytic programs remain unresolved.\",\n      \"evidence\": \"\",\n      \"pmids\": [],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Full-length membrane-embedded human FAAH dimer structure not solved\", \"Substrate hierarchy in vivo not systematically defined\", \"Mechanism of FAAH-dependent microglial reprogramming unknown\"]\n    }\n  ],\n  \"mechanism_profile\": {\n    \"molecular_activity\": [\n      {\"term_id\": \"GO:0016787\", \"supporting_discovery_ids\": [0, 2, 3, 7]},\n      {\"term_id\": \"GO:0140096\", \"supporting_discovery_ids\": [3, 0, 2]}\n    ],\n    \"localization\": [\n      {\"term_id\": \"GO:0005886\", \"supporting_discovery_ids\": [3, 6]},\n      {\"term_id\": \"GO:0005634\", \"supporting_discovery_ids\": [15]}\n    ],\n    \"pathway\": [\n      {\"term_id\": \"GO:1430728\", \"supporting_discovery_ids\": [3, 6, 10, 12]},\n      {\"term_id\": \"R-HSA-162582\", \"supporting_discovery_ids\": [11, 12, 14]},\n      {\"term_id\": \"R-HSA-112316\", \"supporting_discovery_ids\": [11, 14, 16]}\n    ],\n    \"complexes\": [\n      \"FAAH homodimer\"\n    ],\n    \"partners\": [\n      \"IKZF1\",\n      \"ESR2\",\n      \"KDM1A\",\n      \"CNR1\",\n      \"CNR2\"\n    ],\n    \"other_free_text\": []\n  }\n}\n```"}